137 related articles for article (PubMed ID: 38650500)
1. Risankizumab for severe psoriasis: a case of successful retreatment without induction after 15 months of discontinuation.
Mortato E; Baratta S; Viola R; DE Caro AP; Loconsole F
Ital J Dermatol Venerol; 2024 Apr; 159(2):199-200. PubMed ID: 38650500
[No Abstract] [Full Text] [Related]
2. Effects of risankizumab in patients with psoriasis previously treated with guselkumab: a case series.
Lin PH; Tsai TF
Eur J Dermatol; 2021 Apr; 31(2):251-252. PubMed ID: 33875411
[No Abstract] [Full Text] [Related]
3. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
Fioranelli M; Roccia MG; Lotti T
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
[No Abstract] [Full Text] [Related]
4. Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience.
Becatti M; Urban ML; Taurisano G; Mannucci A; Barygina V; Pescitelli L; Prignano F; Silvestri E; Taddei N; Lotti T; Fiorillo C; Emmi G
Dermatol Ther; 2018 Sep; 31(5):e12675. PubMed ID: 30133998
[No Abstract] [Full Text] [Related]
5. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
Papp K; Crowley J; Ortonne JP; Leu J; Okun M; Gupta SR; Gu Y; Langley RG
Br J Dermatol; 2011 Feb; 164(2):434-41. PubMed ID: 21083543
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
8. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
[TBL] [Abstract][Full Text] [Related]
9. First case of secukinumab successful therapy in a very elderly psoriatic patient.
Ricceri F; Pescitelli L; Lazzeri L; Di Cesare A; Prignano F
Dermatol Ther; 2018 Sep; 31(5):e12668. PubMed ID: 30209856
[No Abstract] [Full Text] [Related]
10. Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study).
Orsini D; Assorgi C; Bonifati C; Cameli N; Graceffa D; Potestio L; Megna M
J Dermatolog Treat; 2024 Dec; 35(1):2358150. PubMed ID: 38777338
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of severe refractory psoriasis with infliximab. Clinical outcomes after one year of therapy].
Mahiques Santos L; Martínez Menchón T; Sánchez Carazo JL; Fortea Baixauli JM
Med Clin (Barc); 2005 Jun; 125(4):159. PubMed ID: 15989862
[No Abstract] [Full Text] [Related]
12. Successful treatment of adalimumab-induced paradoxical psoriatic arthritis with risankizumab.
Watabe D; Amano H
Eur J Dermatol; 2020 Oct; 30(5):611-612. PubMed ID: 33185535
[No Abstract] [Full Text] [Related]
13. Response of severe psoriasis to infliximab.
Mang R; Stege H; Ruzicka T; Krutmann J
Dermatology; 2002; 204(2):156-7. PubMed ID: 11937748
[No Abstract] [Full Text] [Related]
14. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M
Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
[TBL] [Abstract][Full Text] [Related]
15. Ustekinumab (Stelara) for psoriasis.
Med Lett Drugs Ther; 2010 Jan; 52(1330):7-8. PubMed ID: 20208473
[No Abstract] [Full Text] [Related]
16. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab.
Umezawa Y; Torisu-Itakura H; Morisaki Y; ElMaraghy H; Nakajo K; Akashi N; Saeki H;
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):568-576. PubMed ID: 30325534
[TBL] [Abstract][Full Text] [Related]
17. Practical experience of biologics for treatment of very severe psoriasis: a retrospective case cohort study of patients with a baseline Psoriasis Area and Severity Index greater than 20.
Ponnambath N; Kalavala M; Anstey AV; Piguet V; Ingram JR
Clin Exp Dermatol; 2016 Jan; 41(1):95-6. PubMed ID: 25817265
[No Abstract] [Full Text] [Related]
18. Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).
Strober B; Bachelez H; Crowley J; Elewski BE; Gooderham M; Menter A; Strohal R; Chen MM; Wu T; Zhan T; Photowala H; Armstrong A
J Eur Acad Dermatol Venereol; 2024 May; 38(5):864-872. PubMed ID: 38179809
[TBL] [Abstract][Full Text] [Related]
19. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type.
Newland MR; Weinstein A; Kerdel F
Int J Dermatol; 2002 Jul; 41(7):449-52. PubMed ID: 12121565
[TBL] [Abstract][Full Text] [Related]
20. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.
Castiñeiras I; Fernández-Diaz L; Juárez Y; Lueiro M
J Dermatol; 2012 Aug; 39(8):730-1. PubMed ID: 22364316
[No Abstract] [Full Text] [Related]
[Next] [New Search]
